Abstracts Archive - Page 370 of 2607 - ACR Meeting Abstracts

Abstract Number: 1087 • ACR Convergence 2023
Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach
Sara Faghihi-Kashani, Arooj Babar and Janice Lin, Stanford University, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…
Abstract Number: 1105 • ACR Convergence 2023
Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients
Jinseok kim, Division of Rheumatology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, South Korea
Background/Purpose: Many studies have reported that gout and hyperuricemia are associated with an increase in all-cause mortality and cardiovascular mortality.Increased vascular stiffness is closely related…
Abstract Number: 1109 • ACR Convergence 2023
Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis
Blanka Stiburkova¹, Katerina Pavelcova², Jana Masinova¹, Marketa Pavlikova³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology, Praha 2, Czech Republic, ³Department of Probability and Mathematical Statistics, Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Hyperuricemia is a central feature in the pathogenesis of gout. Hyperuricemia results from an imbalance between endogenous production and excretion of urate; however, the…
Abstract Number: 1112 • ACR Convergence 2023
AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Zancong Shen¹, Elizabeth Polvent², sarah Morris³, Rongzi Yan⁴, Shunqi Yan⁵, Robert Keenan⁶ and Li-Tain Yeh⁷, ¹Arthrosi Therapeutics, San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Arthrosi Therapeutics Inc, San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Chapel Hill, NC, ⁷Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: The uric acid transporter inhibitor (URAT1) is responsible for the reabsorption of filtered uric acid from the renal tubular lumen. Uricosuric agents inhibit URAT1…
Abstract Number: 1101 • ACR Convergence 2023
Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia
Maria-Luisa Peral-Garrido¹, Paula Boix-Navarro², Silvia Gómez-Sabater³, Rocío Caño-Alameda³, Alejandra Bermúdez-García⁴, Teresa Lozano⁴, Ruth Sanchez-Ortiga⁴, Miguel Perdiguero⁴, Elena Caro-Martínez⁵, Carolina Ruiz-García⁶, Eliseo Pascual⁴, Rubén Francés² and Mariano Andrés⁴, ¹Vinalopó University Hospital, Novelda, Spain, ²Miguel Hernandez University, San Juan de Alicante, Spain, ³Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ⁴Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁵San Vicente Hospital-HACLE, San Vicente del Raspeig, Spain, ⁶Campoamor Health Centre, Alicante, Spain
Background/Purpose: Whether the presence of subclinical monosodium urate (MSU) crystal deposition leads to a pro-inflammatory state in asymptomatic hyperuricemia (AH) is unknown. We aimed to…
Abstract Number: 1120 • ACR Convergence 2023
Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients
Natalie McCormick¹, Chio Yokose², Gregory Challener¹, Amit Joshi³, Sruthi Tanikella¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Channing Division of Network Medicine, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Despite rheumatology guidelines' emphasis on treat-to-target-serum-urate (SU) levels (<6 or <5 mg/dL, urate crystal sub-saturation points), this pathophysiology-based recommendation is not accepted in primary…
Abstract Number: 1119 • ACR Convergence 2023
Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice
Silvia Sirotti¹, Joao Madruga-Dias², Antonella Adinolfi³, Garifallia Sakellariou⁴, Davide Rozza⁵, Greta Carrara⁵, Gianpiero Landolfi⁵, Carlo Alberto Scire⁵, Annamaria Iagnocco⁶ and Georgios Filippou¹, ¹IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy, ²Centro Hospitalar do Médio Tejo, NOVA Medical School, Lisbon, Portugal, ³Rheumatology Unit, Grande Ospedale Metropolitano Niguarda, Milano, Italy, ⁴Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ⁵Società Italiana di Reumatologia, Epidemiology Research Unit, Milan, Italy, ⁶University of Turin, Roma, Italy
Background/Purpose: The RADIAL study is aimed to evaluate the performance of a composite approach, based on clinical, laboratory and ultrasound (US) data in the differential…
Abstract Number: 1086 • ACR Convergence 2023
Increase Shingrix Vaccination Rate in Patients on JAK Inhibitors: A Quality Improvement Project at the Rheumatology Practice of an Urban Institution
Jin Feng¹ and Kristaq Koci², ¹Icahn School of Medicine at Mount Sinai Morningside and West, New York, NY, ²Icahn School of Medicine at Mount Sinai Morningside and West, Bronx, NY
Background/Purpose: The 2022 ACR guidelines for vaccination strongly recommend recombinant VZV vaccination for all patients > 18 years old who are taking immunosuppressive medication. Studies…
Abstract Number: 1056 • ACR Convergence 2023
Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study
Alexandra Ladouceur¹, Gael Mouterde², Alice TISON³, Samuel Bitoun⁴, Sorilla Mary-Prey⁵, Caroline Dutriaux⁶, Emilie Gerard⁵, Anne Pham-Ledard⁵, Marie Beylot-Barry⁵, Maeva Zysman⁵, Rémi Veillon⁵, Charlotte Domblides⁷, Amaury Daste⁷, Marine Gross-Goupil⁷, Baptiste Sionneau⁷, Félix Lefort⁷, Mathieu Larroquette⁷, Thomas Barnetche⁸, Christophe Richez⁹, Marie-Elise Truchetet⁸, Thierry Schaeverbebke¹⁰ and Marie Kostine⁸, ¹Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, ²CHU Lapeyronie, Montpellier, France, ³CHU de la Cavale Blanche, Brest, France, ⁴Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184, Paris, France, ⁵Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, ⁶CHU-Bordeaux, Bordeaux, France, ⁷Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, ⁸Bordeaux University Hospital, Bordeaux, France, ⁹Université de Bordeaux, Bordeaux, France, ¹⁰University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI) improve overall survival in many cancer patients by activating their immune system. However, they can cause off-target immune-related adverse events…
Abstract Number: 1107 • ACR Convergence 2023
Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
James Mossell¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux² and Sanjay Chabra³, ¹Arthritis and Osteoporosis Center of South Georgia, Tifton, GA, ²Horizon Therapeutics, Deerfield, IL, ³Texas Arthritis Center, El Paso, TX
Background/Purpose: Pegloticase can lower serum urate (SU) in patients with uncontrolled gout who are refractory to/intolerant of oral urate-lowering therapies. However, antidrug antibodies (ADAs) can…
Abstract Number: 1092 • ACR Convergence 2023
Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous
Lilian Otalora Rojas¹, Gurjit S Kaeley² and Myint Thway³, ¹University of Florida, Ponte Vedra Beach, FL, ²University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL, ³UF Jacksonville, Ponte Vedra, FL
Background/Purpose: Nephritis remains one of the most devastating complications of Systemic lupus erythematosus (SLE). Lupus nephritis (LN) significantly reduces overall survival to approximately 88% at…
Abstract Number: 1115 • ACR Convergence 2023
EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice
Peter Mandl¹, Maria-Antonietta D'Agostino², Victoria Navarro-Compán³, Irina Gessl¹, Garifallia Sakellariou⁴, Abhishek Abhishek⁵, Fabio Becce⁶, Nicola Dalbeth⁷, Hang-Korng Ea⁸, Emilio Filippucci⁹, Hilde Berner Hammer¹⁰, Annamaria Iagnocco¹¹, Annette De Thurah¹², Esperanza Naredo¹³, Sebastien Ottaviani¹⁴, Tristan Pascart¹⁵, Fernando Perez-Ruiz¹⁶, Irene Pitsillidou¹⁷, Fabian Proft¹⁸, Juergen Rech¹⁹, Wolfgang Schmidt²⁰, Luca Sconfienza²¹, Lene Terslev²², Brigitte Wildner²³, Pascal Zufferey²⁴ and Georgios Filippou²⁵, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Universita Cattolica del Sacro Cuore Rome, Courbevoie, France, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Department of Internal Medicine and Therapeutics, Università di Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, ⁵University of Nottingham, Nottingham, United Kingdom, ⁶Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁷University of Auckland, Auckland, New Zealand, ⁸Hôpital Lariboisière, APHP-Nord, Service de Rhumatologie, Université de Paris Cité, Paris, France, ⁹Polytechnic University of Marche, Jesi, Italy, ¹⁰Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway AND University of Oslo, Faculty of Medicine, Oslo, Norway, ¹¹University of Turin, Roma, Italy, ¹²Aarhus University Hospital, Aarhus, Denmark, ¹³Hospital Fundación, Madrid, Spain, ¹⁴Assistance Publique Hopitaux de Paris, Paris, France, ¹⁵Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ¹⁶Rheumatology Division, Osakidetza, OSI-EE Cruces, Cruces University Hospital, Barakaldo, Spain, ¹⁷EULAR Patient Research Partner, Executive Secretary of Cyprus League Against Rheumatism, Nicosia, Cyprus, ¹⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ¹⁹University Clinic Erlangen, Erlangen, Germany, ²⁰Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ²¹Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano AND IRCCS Istituto Ortopedico Galeazzi, 20161, Milan, Italy, ²²Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ²³University Library, Medical University of Vienna, Vienna, Austria, ²⁴Rheumatology Department, University of Lausanne, CHUV, Lausenne, Switzerland, ²⁵IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy
Background/Purpose: The multifaceted clinical presentation in crystal-induced arthropathies (CiA) poses challenges to imaging. Our goal was to formulate evidence-based recommendations on the use of imaging…
Abstract Number: 1114 • ACR Convergence 2023
Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout
Muhammad Danish Sarfraz, Lee Treanor, Savvas Nicolaou and Adnan Sheikh, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To find out if a Dual energy CT can detect monosodium urate deposition in carotid arteries and whether the presence of monosodium urate crystals…
Abstract Number: 1117 • ACR Convergence 2023
Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis
Chio Yokose¹, Gregory Challener², Baijun Zhou², Natalie McCormick², Sruthi Tanikella², Kila Panchot², Minna Kohler³, Janeth Yinh², Yuqing Zhang⁴, David Bates⁵, James Januzzi², Meghan Sise², Deborah Wexler² and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Waltham, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are currently indicated as second-line therapy for type 2 diabetes and are also approved for the treatment of…
Abstract Number: 1111 • ACR Convergence 2023
Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis
Palapun Waitayangkoon¹, Tatchaya Kanthajan² and Thiratest Leesutipornchai³, ¹MetroWest Medical Center, Framingham, MA, ²Srinakharinwirot University, Bangkok, Thailand, ³University of Hawaii, Honolulu, HI
Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].